Madopar Lt (Benserazide Hydrochloride, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, the neurotransmitter deficient in Parkinsonian disorders. Benserazide inhibits the peripheral enzyme dopa decarboxylase, preventing early conversion of levodopa outside the brain. This combination ensures more levodopa reaches the central nervous system, enhancing dopaminergic signaling.

The dose of Madopar LT is individualized and set by the prescribing physician based on the patient’s clinical response, disease stage, and tolerability. Dosage adjustments are made during treatment to achieve optimal symptom control while minimizing side effects.

Safety data for Madopar LT in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the risks and consider alternative therapies when appropriate.

To request Madopar LT, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative is the levodopa/carbidopa combination (e.g., Sinemet). Both pairs provide levodopa with a peripheral decarboxylase inhibitor, but benserazide differs chemically from carbidopa. Clinical efficacy is comparable; choice often depends on regional availability, patient tolerance, and physician preference.

Madopar LT tablets should be stored at ambient temperature below 25 °C, in their original blister pack, and protected from moisture and direct sunlight. Do not refrigerate or freeze the product, and keep it out of reach of children.

Madopar LT is taken orally as an extended‑release tablet. The tablet should be swallowed whole with a glass of water, preferably with food to reduce gastrointestinal irritation. Patients should follow the dosing schedule prescribed by their clinician and avoid crushing or chewing the tablet.

Serious adverse reactions include dyskinesia (involuntary movements), hallucinations or psychosis, severe hypotension or syncope, neuroleptic malignant syndrome, and rare allergic reactions such as angioedema. Patients should be monitored closely for these events, and any sudden changes should prompt immediate medical evaluation.

Madopar LT is contraindicated in individuals with known hypersensitivity to levodopa, benserazide, or any excipients in the formulation. Caution is advised for patients with narrow‑angle glaucoma, severe cardiovascular disease, or a history of melanoma. The drug should be avoided in these populations unless a specialist determines that benefits outweigh risks.